by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
– Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers – – Posters Highlighting Predictive Biomarkers of Selinexor Activity in Preclinical Models of Gynecological and Colorectal Cancers – NEWTON, Mass., July 27, 2016...
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
– Same-Store Sales Growth of 2.5% – – Completes $10 Million Stock Buyback Plan; Slows Development Pace Beginning in 2017 to Increase Company’s Earnings Power and Provide Greater Flexibility for Use of Capital – – Revises 2016 Annual...
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
Revenues: $401 million, up 4.4% from second quarter of 2015Operating Margin: 6.0% for the second quarter, operating income up 15% from second quarter of 2015 Diluted EPS: $0.39, up 18% from second quarter of 2015 Book-to-Bill Ratio: 1.2 for the second quarter and year...
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis®...
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
Second quarter 2016 net revenue of $311.7 million, as compared to $288.8 million in the comparable prior year quarter, increase of 7.9%.Second quarter 2016 GAAP net income of $16.0 million, as compared to $3.7 million in the comparable prior year quarter. Second...
